Ophthalmic compositions of rifamycins and uses thereof

Abstract

Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

1 . A method of treating an ocular disease, disorder or condition resulting from neovascularization comprising topically administering to a patient in need thereof a pharmaceutically acceptable ophthalmic ointment composition comprising:
 an effective amount of a rifamycin compound selected from the group consisting of rifampicin, rifabutin, rifapentine and rifaximin, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable viscosity inducing agent.   
     
     
         2 . The method of  claim 1 , wherein the ocular disease, disorder or condition is selected from age related macular degeneration (AMD), ocular neovascularization, or retinal ganglion cell injury. 
     
     
         3 . The method of  claim 2 , wherein the ocular neovascularization comprises retinal neovascularization. 
     
     
         4 . A method of inhibiting ocular neovascularization in a retina of a patient in need thereof, comprising administering topically a pharmaceutically acceptable ophthalmic ointment composition comprising up to about 1% (w/v) of rifampicin, and one or more pharmaceutically acceptable viscosity inducing agent to an eye of the patient. 
     
     
         5 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition comprises from about 0.1% to about 1% of rifampicin. 
     
     
         6 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition comprises from about 0.25% to about 1% of rifampicin. 
     
     
         7 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition comprises from about 0.5% to about 1% of rifampicin. 
     
     
         8 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition comprises from about 0.1% to about 0.5% of rifampicin. 
     
     
         9 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition comprises from about 0.25% to about 0.5% of rifampicin. 
     
     
         10 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition comprises from about 0.25% of rifampicin. 
     
     
         11 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition comprises from about 0.5% of rifampicin. 
     
     
         12 . The method of  claim 1 , wherein the pharmaceutically acceptable ophthalmic ointment composition further comprises from about 0.1 wt %-10 wt % of a surfactant selected from polysorbate 80, tween 80, tween 20, polyoxyethylene hydrogenated castor oil, and lecithin, or combinations thereof. 
     
     
         13 . The method of  claim 4 , wherein the pharmaceutically acceptable ophthalmic ointment composition further comprises about 0.1 wt %-10 wt % of a surfactant selected from polysorbate 80, tween 80, tween 20, polyoxyethylene hydrogenated castor oil, and lecithin, or combinations thereof. 
     
     
         14 . The method of  claim 1 , wherein the one or more pharmaceutically acceptable viscosity inducing agent is selected from the group consisting of carboxyvinyl polymer, a cellulosic polymer, a polysaccharide, polyvinyl pyrrolidone, polyvinyl alcohol, and combinations thereof. 
     
     
         15 . The method of  claim 4 , wherein the one or more pharmaceutically acceptable viscosity inducing agent is selected from the group consisting of carboxyvinyl polymer, a cellulosic polymer, a polysaccharide, polyvinyl pyrrolidone, polyvinyl alcohol, and combinations thereof. 
     
     
         16 . A method of inhibiting ocular neovascularization in a retina of a patient in need thereof, comprising administering topically a pharmaceutically acceptable ophthalmic ointment composition comprising from about 1% to about 10% (w/v) of rifampicin, and one or more pharmaceutically acceptable viscosity inducing agent to an eye of the patient. 
     
     
         17 . The method of  claim 16 , comprising from about 1.5% to about 5% (w/v) of rifampicin. 
     
     
         18 . The method of  claim 16 , comprising from about 2% to about 2.5% (w/v) of rifampicin.